Overview

VBL Therapeutics is an innovative, clinical-stage biotechnology company developing new treatments for immune-inflammatory diseases, including psoriasis. We are also developing new drugs to fight cancer, including thyroid cancer.

We recently completed dosing of our lead compound, VB-201, in Phase 2 clinical studies evaluating VB-201 for the treatment of psoriasis and inflammation in atherosclerosis. 

VBL Therapeutics’ proprietary Vascular Targeting System (VTS™) technology platform has yielded VB-111, a highly targeted anti-angiogenic agent for the specific inhibition of tumor vascular growth, which recently entered Phase 2 clinical trials in thyroid cancer and glioblastoma. 

Clinical Targets

Psoriasis and Other Inflammatory Diseases

VBL Therapeutics is pioneering a new class of drugs to treat immune-inflammatory conditions. We have developed a series of proprietary phospholipid analogs from the Lecinoxoid family that are rationally designed as oral medications to address the substantial unmet needs in immune-inflammatory diseases.

The lead compound from this program is VB-201, which has significant potential as a specific, targeted, oral disease-modifying agent for the control of chronic inflammatory diseases including psoriasis, rheumatoid arthritis, atherosclerosis, inflammatory bowel disease and multiple sclerosis. VB-201 holds the promise of specifically modulating patients’ immune systems, thereby reducing the frequency and severity of flare-ups associated with chronic inflammatory diseases, and ultimately allowing patients to avoid the adverse events associated with treatments that systemically target the immune system.

Cancer

Our innovative, proprietary platform technology, VTS™ (Vascular Targeting System), enables control of gene expression to areas in which angiogenesis is taking place to either promote or destroy newly formed blood vessels. VTS is both tissue- and condition-specific, allowing for targeted and limited expression to endothelial cells undergoing angiogenesis.

The VTS platform allows us to develop several different products targeting various diseases where angiogenesis is a defining feature. We have used this technology to develop two therapeutic compounds: VB-111 for oncology and VB-201 for ischemic diseases.